Business
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
Lead therapeutic candidate for Alzheimer’s disease, PMN310, demonstrated selective binding and protection against toxic amyloid-beta oligomersPreclinical data
About this update from Promis Neurosciences Inc.
[{"type":"text","content":"Lead therapeutic candidate for Alzheimer’s disease, PMN310, demonstrated selective binding and protection against toxic amyloid-beta oligomersPreclinical data support misfolded RACK1 as a potential target for ALS and FTLD-TDP TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 24, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced data supporting the receptor of activated C-kinase 1 (RACK1) as a potential target in ALS and frontotemporal lobar degeneration with TPD-43-immunoreactive pathology (FTLD-TDP), and updated preclinical data from the Company’s lead candidate for AD, PMN310. The data were presented in poster presentations on April 23 at the 75th American Academy of Neurology (AAN) Annual Meeting in Boston, MA. “We are pleased to share progress highlighting our ongoing effort to develop next-generation therapies for debilitating neurodegenerative disorders,” said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences. “We are excited to share the data differentiating our lead therapeutic candidate for Alzheimer’s disease, PMN310, which exhibited characteristics in preclinical studies that may provide greater therapeutic potential and support a favorable tolerability profile compared to other amyloid-beta antibodies. AAN is also a great opportunity to present our data supporting the potential of misfolded RACK1 as a novel target for ALS and also FTLD-TDP, and our ability to generate antibodies that selectively bind aggregated RACK1 while avoiding benign isoforms.” AAN Poster Details Title: Protection Against Toxic Amyloid-beta Oligomers by PMN310, a Monoclonal Antibody Rationally Designed for Greater Therapeutic Potency in Alzheimer’s DiseaseSession: P1: Aging and Dementia: Basic Science (abstract #4597) Presenter: Johanne Kaplan, Ph.D.Date & Time: April 23, 2023 from 8:00 – 9:00 a.m. ET Evidence suggests that soluble toxic amyloid-beta (Aβ) oligomers, rather than Aβ monomers or plaque, are a primary driver of synaptic dysfunction, neuronal loss and cognitive decline in AD patients. However, it is difficult to sp...